Author: NewsCancer

At the 2026 National ICE-T Conference in Orlando, CancerNetwork® sat down with a variety of expert researchers and clinicians to discuss the latest developments in immune effector therapy across different hematologic oncology populations. Sessions at the meeting covered practical considerations for integrating CAR T-cell therapies, bispecific antibodies, and other modalities into the treatment of those with multiple myeloma, lymphoma, and other hematologic malignancies.First, Benjamin Diamond, MD, an assistant professor of Clinical Medicine, a member of the Sylvester Myeloma Institute, and a member of the Myeloma Genomic Lab at the University of Miami Miller School of Medicine, spoke about his presentation…

Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss the growing number of BCMA-directed bispecific antibody options available for patients with relapsed/refractory multiple myeloma (RRMM) and the practical considerations that influence treatment selection.The faculty emphasize that, despite differences in administration schedules, formulations, toxicity profiles, and clinical trial designs, currently available BCMA-directed bispecific antibodies have demonstrated meaningful clinical activity across heavily pretreated patient populations.Dr. Huff highlights the importance of institutional experience, formulary availability, and familiarity with toxicity management when incorporating these therapies into practice.Dr. Mewawalla discusses how access to multiple agents allows for individualized treatment discussions and shared…

CDCA-mediated tumor growth inhibition is driven by immune responsesTo investigate the effects of CDCA on tumor growth, C57BL/6J mice aged 6 weeks were randomized to receive either vehicle or 5 mg/kg CDCA via oral gavage to establish tumor models in mice. (Fig. 1a). Two weeks after gavage administration, no significant difference in body weight was observed between the CDCA-treated and vehicle control mice (Supplementary Fig. 1a–e). Subcutaneous tumor xenograft models were established in mice via syngeneic MC38 colon cancer cells, B16‒F10 melanoma cells, B16‒OVA melanoma cells, 4T1 breast cancer cells, or LLC Lewis lung cancer cells. Interestingly, MC38 and B16-OVA tumors,…

AnimalsAll animal experiment protocols were approved by the Institutional Animal Care and Use Committee (IACUC) (INHA 230827-886) of Inha University. All animals were purchased from Orient Bio Inc. (Charles River, Korea). Animals were housed at the university-operated housing facility and monitored daily by a professional. Animals were additionally monitored by the researchers at least once every two days and euthanized upon reaching predefined humane endpoints approved by the IACUC, including significant body weight loss or excessive tumor burden. The tumor volumes were measured using calipers. Tumor volumes were calculated as {(length) × (width)2 × 0.5}, where length and width denote the longest and shortest…

Football supporters are being encouraged to compete for their club in a prostate cancer fundraising campaign.Prostate United was set up in 2018 by Stephen Gilpin, assistant director of performance at Wolverhampton Wanderers, along with former colleague Ross Burbeary.Gilpin said he launched Prostate United in memory of his grandfather, Norman, who died from prostate cancer in 2010. He said: “Losing my grandad to prostate cancer had a huge impact on my family and inspired me to do something that could make a real difference.”Gilpin added: “Football has an incredible ability to bring people together, regardless of who you support, and that’s…

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.Article  PubMed  PubMed Central  Google Scholar  Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al. Head and neck cancers, version 2.2014. J Natl Compr Cancer Netw. 2014;12:1454–87.Article  Google Scholar  Berzenji D, Sewnaik A, Keereweer S, Monserez DA, Verduijn GM, van Meerten E, et al. Dissemination patterns and chronology of distant metastasis affect survival of patients with head and neck squamous cell carcinoma. Oral Oncol. 2021;119:105356.Article  PubMed  Google Scholar  Pisani P, Airoldi M, Allais…

Chemoresistance remains a major obstacle in colorectal cancer (CRC) treatment. In this study, we performed an integrative multi-omics analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, combined with machine learning approaches, to systematically investigate the UFMylation pathway in CRC. The E2 conjugating enzyme UFC1 was identified as a key determinant of chemotherapy sensitivity, with copy number amplification and elevated expression in tumors, particularly in chemotherapy-responsive patients. Single-cell transcriptomics revealed UFC1 enrichment in malignant epithelial cells, and its expression correlated with DNA damage response and apoptosis pathways. A LASSO-Cox risk model incorporating UFM1 pathway genes effectively…

At the 2026 National ICE-T Conference in Orlando, a session titled “Thresholds and Therapeutics: A Precision Approach to CAR T Toxicity Management” examined how biomarkers, including CAR T-cell expansion, may help clinicians anticipate toxicity risk with anti-BCMA CAR T-cell products.1Presenter Tiba Al Sagheer, PharmD, BCOP, BCACP, pharmacy quality improvement coordinator for transplant and cellular therapy at Miami Cancer Institute of Baptist Health South Florida, spoke with CancerNetwork® about how balancing early toxicity intervention against the risk of blunting efficacy differs by CAR T-cell product.Transcript:CancerNetwork: Speaking as a pharmacist, how do you balance early aggressive intervention against the risk of blunting…

The NHS estimates that around 17,500 men are diagnosed with low or intermediate-risk prostate cancer in England every year and could be offered SABR radiotherapy.This makes up nearly a third of the 55,000 diagnosed annually with the most common form of cancer among men.The treatment uses advanced imaging to deliver radiation to the prostate with pinpoint accuracy, minimising damage to surrounding healthy tissue – and therefore reducing side effects.NHS England said in June it expected all 48 radiotherapy centres around the country to start offering the treatment “within weeks”.Chase, who finished his treatment in June, said it was more convenient…

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.PubMed  Google Scholar  Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611–25.Article  PubMed  Google Scholar  Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345–56.Article  PubMed  Google Scholar  Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.Article  PubMed  Google Scholar  Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.Article  PubMed  Google Scholar  Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements…